In Its Path Towards Marketing, Pluristem Provides Highly Favorable Market Access Data Regarding the Critical Limb Ischemia Market in U.S.
03 févr. 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study
17 déc. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment
03 déc. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Therapeutics CEO Issues Shareholder Update
12 nov. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare
04 nov. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
RESTORE Consortium, of which Pluristem is a leading member, is competing for up to a €1 billion award by the European CommissionWinner announcement is expected in May 2020 HAIFA, Israel, Nov. ...
Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs
16 sept. 2019 12h20 HE
|
Pluristem Therapeutics, Inc.
PLX-R18 is currently in development as a countermeasure for acute radiation syndrome and as a treatment for incomplete recovery following hematopoietic cell transplantationData from 1st and 2nd...
Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs
09 sept. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced...
Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs
21 août 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome
31 juil. 2019 08h00 HE
|
Pluristem Therapeutics, Inc.
PLX-R18 demonstrated significant increase in survival rates and recovery of the three blood lineagesData is jointly presented at the 2019 Radiation Injury Treatment Network (RITN) Workshop HAIFA,...
Pluristem Therapeutics’ CEO Issues Shareholders Update
24 juil. 2019 10h45 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...